Savara reports Q4 EPS (7c), consensus (7c)

As of December 31, 2022, the Company had cash, cash equivalents and short-term investments of $125.9 million. "Enrollment in the pivotal Phase 3 IMPALA-2 trial remains on-track, and we continue to anticipate reporting top line safety and efficacy data by the end of 2Q 2024," said Matt Pauls, Chair and CEO, Savara. "As we approach the milestone of enrollment completion, I am proud of the team’s ability to advance the molgramostim development program during the headwinds of the COVID pandemic. That operational focus will extend to the launch of a global aPAP market development campaign in the second half of the year. Finally, in 2022 we maintained our track record of fiscal discipline and believe we are fully capitalized through 2025."